FPT Software Secures Multiple Wins at 2024 International Business Awards®
28.8.2024 09:00:00 EEST | Business Wire | Press release
Global IT service provider FPT Software has been named winner in three distinctive categories at the 21st Annual International Business Awards® (IBAs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827725587/en/
(Graphic: Business Wire
Bringing its latest digital solutions and products to compete with over 3,600 nominations from various industries, FPT Software has been recognized as the winner in three Business Technology Solution categories:
- Gold Stevie for Artificial Intelligence/ Machine Learning Solution - Financial - Ivychat
- Bronze Stevie for Artificial Intelligence/ Machine Learning Solution - Generative - CodeVista
- Bronze Stevie for Healthcare Technology Solution - Smart Medication Management Platform
In particular, FPT Software’s Ivychat, an advanced AI platform, wins Gold Stevie® for its ability to automate business processes across industries by leveraging large language models (LLMs). Specifically designed to support data management, Ivy seamlessly integrates with existing systems, excelling in lead management, data insights generation, and identifying repurchase opportunities, particularly in the financial services sector.
CodeVista, FPT Software’s AI-powered coding assistant that revolutionizes the entire software development lifecycle, is named Bronze Stevie®. Backed by rigorous research and development, CodeVista is recognized for its ability to transform innovative concepts into powerful, real-world products. It elevates the developer experience by significantly boosting productivity, enhancing code quality, and optimizing processes across all stages—from initial development and modernization to the secure, scalable deployment of innovative applications. This platform also ensures that every phase is seamlessly integrated with the latest AI advancements. Codevista has been successfully implemented in selected projects within FPT Software, leading to a 48% increase in productivity, projected to save $2 million in costs by 2025.
Another Bronze Stevie® is FPT Software's Smart Medication Management Platform. This platform is designed to assist an international healthcare service provider in enhancing connectivity and engagement within the healthcare ecosystem while supporting its global market expansion. It offers high scalability, availability, and security, allowing smooth deployment across data centers in different regions.
"These award-winning solutions are parts of our extensive offerings to drive digital and AI transformation. As the demand for advanced technologies accelerates, FPT Software remains committed to enhancing our solutions to deliver cutting-edge innovations, helping enterprises boost productivity, streamline workflows, and optimize costs. Combining our proven technology expertise, strong global presence, and scalable workforce, we are confident to support our clients at every stage of their digital transformation journey," said Dao Duy Cuong, FPT Software’s Executive Vice President and Chief Digital & Technology Officer.
The International Business Awards are the world’s premier business awards program. This year, the program received entries from organizations in 62 nations and territories, recognizing outstanding workplace performances worldwide.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827725587/en/
Contacts
Media
Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom